NO AI. review the folliwing information and provide a possible reply as a DNP student. 300 words, references 2020-2026, different from post
tam w4
Approved PICOT Question
Among healthcare providers prescribing medications for adults aged 65 years and older in a primary care clinic (P), how does implementation of the 2023 American Geriatrics Society Beers Criteria through provider education, a clinical decision-making tool, and audit and feedback (I), compared with current prescribing practices (C), affect provider knowledge and adherence to evidence-based prescribing recommendations and reduce potentially inappropriate medications (O) over eight weeks (T)?
Week 4 Goals:
Week 4 focuses on renal function, dosing, and risk-based monitoring. It is designed to follow the first week's implementation, where all provider education, the pre-implementation knowledge survey, the decision tool based on the Beers criteria, and preliminary chart review procedures have been implemented. The goal of Week 4 is to build upon that foundation and not simply replicate the introduction from Week 1 as if the project was starting over. Therefore, the objective will be to move that preparation into a more reliable daily assessment of prescribing practices. The objectives will be to assess whether or not providers consider a patient's kidney function when they assess the relevant medications being prescribed; assess how monitoring risk mitigation is documented when a PIM continues to be prescribed; and complete a process evaluation at the midpoint of the study to determine if the collection of audit data is both complete and consistent. As stated previously, these objectives do not introduce new intervention components or outcome measures but instead maintain those that were previously reviewed and approved.
One of the most important principles during implementation has been to recognize that while "polypharmacy" is typically defined by medication count, it does not equate to inappropriate prescribing. For example, an elderly person with multiple chronic conditions may require multiple medications, but their prescription regimen could be small and still include one avoidable high-risk medication. Thus, this project is focused on the clinical appropriateness of each individual agent, documented decisions regarding those agents, and provider compliance with evidence-based recommendations. The 2023 AGS Beers Criteria provides five interrelated domains for evaluating potential misuse of drugs, including drug selection, disease-related cautionary statements, drug-drug interaction risks, and consideration of renal issues (American Geriatrics Society Beers Criteria Update Expert Panel., 2023).
Activities for Week 4
For each week of implementation, the project will begin with a short meeting with the preceptor to clarify what patient encounters will be eligible for inclusion in the project and answer any questions regarding documentation from the previous week. Although each week of the project will have a theme, the feedback shared in Week 1 will serve as the basis for future feedback as well. Any providers that were unavailable during the original educational session in Week 1 will need to receive make-up sessions and document that supplemental education was provided. It will be reiterated that this education is not to simply memorize medications that should or shouldn’t be prescribed but rather to learn strategies on how to apply the decision tool and incorporate its teachings into medication prescribing decisions.
Any questions regarding medications or prescribing decisions that seem questionable can be discussed with the preceptor with reference to the definitions within the protocol. The Beers criteria do provide guidance on situations when a medication could still be prescribed despite being on the list or require extra vigilance with monitoring, kidney function, or dosage changes. If it’s unclear whether or not the prescribing decision was “inappropriate,” the encounter can remain labeled as "indeterminate” rather than make assumptions.
Medical records will be reviewed for adults age sixty-five and over to include medications prescribed, indications, diagnosis, monitoring, and any pertinent health care provider documentation. When applicable, documentation of lab values or kidney function will be reviewed for medications prescribed that are indicated within the Beers Criteria tool as pertinent for kidney function. Polypharmacy is often thought of in terms of the number of medications prescribed, although this term does not necessarily imply "polypharmacy"; for example, an older adult may have three chronic conditions that would require a minimum of three medications to manage. Conversely, a smaller number of medications could still contain at least one unnecessary high-risk medication. Therefore, this project is focusing more on the appropriateness of medications prescribed, justification and rationale for prescribing decisions, and use of evidence-based practices and tools for prescribing guidance. The 2023 American Geriatrics Society (AGS) Beers Criteria tool divides considerations into five parts: Drug Selection, Disease-Related Cautions, Drug-Drug Interactions, Renal Considerations, and Additional Cautions (American Geriatrics Society Beers Criteria Update Expert Panel., 2023). It will be imperative for the reviewer to pay attention to whether or not the medication is just a PIM or if extra considerations, dose adjustments, or exceptions apply when conducting the chart reviews. Documentation stating "medications reviewed” does not indicate whether or not the Beers Criteria for prescribing was considered. If a medication prescribed is a PIM, it would be helpful to see provider documentation explaining the indication for the medication, the reasoning behind the decision that benefits outweigh risks, and monitoring for response to therapy and side effects.
Data collection would then occur using the approved audit and feedback tracking tool. Documentation would indicate whether or not a medication review/reconciliation took place, if a PIM was prescribed, the rationale for prescribing decisions if it’s a PIM, and a follow-up plan (i.e., discontinue medication, reduce medication dose, try a different medication, increase monitoring, patient education/counseling, referral for more comprehensive medication review, etc.). It is important to reiterate this project is not recommending medications not be prescribed or that decisions made by health care providers aren’t individualized to the patient. Conducting medication reviews for quality improvement projects during protected times is outlined within Essential III (Clinical Scholarship & Analytical Methods) in the American Association of Colleges of Nursing (AACN) Doctoral Framework for Nursing Education (American Association of Colleges of Nursing, 2006).
Aggregated de-identified information would be shared back with the clinicians for the week’s chart reviews in a nonjudgmental format with the hopes that at least one or two items could be utilized to further improve prescribing habits and/or documentation.
Positive Elements of Week 4
As described in the Week 1 report, providers have been constructive participants, and the data-collection tool appears feasible. Week 4 evaluation targets are (1) determine whether clinicians will use the brief, structured decision tool during regularly scheduled patient visits and (2) determine whether the project continues to have the support of the preceptor and leadership of the clinic.
More consistent documentation of clinical rationale/indication for medication therapy and fewer unclear scenarios would be a meaningful continuation of the previously described positive trend. Provider willingness to engage in further discussion about a potential PIM instead of perceiving the alert as indicative of a prescribing error would also continue a previously described positive trend. However, it will be important to reflect upon only those examples in Week 4 where this phenomenon has actually occurred and document this in the table.
It is important to evaluate not only the number of medications prescribed but also the risks of those medications (Costanzo et al., 2024). However, although this publication provides important background information about polypharmacy and associated outcomes in the older adult, the clinic’s own findings must be established through the project audit and cannot be inferred from published prevalence or association studies.
Unexpected Events or Challenges During Week 4
It would be important to explore whether there have been any implementation challenges. For instance, a recent laboratory value may not be available in the encounter record, preventing a reliable judgment about renal-dose appropriateness.
It was previously described in the Week 1 report that medication reconciliation varies and relevant medication information can be difficult to locate in the chart. It will be important to explore whether this issue continues to be a challenge during data collection. When documentation is unclear, it can be easy to make an inaccurate determination; the prescription could be outdated, there may have been a good reason to continue the PIM or a taper could have been in place.
If additional challenges arise during implementation (clinician availability for feedback, unclear reason for medications prescribed by other specialists, varying complexity of qualifying visits, etc.), these should also be described in this section. It will be important to report whether there have been any challenges and provide examples in this section.
Adjustments Needed for Week 5
One possible adjustment would be to: Strengthen attention to deprescribing discussions, patient goals, and individualized alternatives. This is a modification to the workflow/implementation process and not a change to the PICOT. This proposed intervention uses the Beers Criteria to raise awareness about the possible value in reducing the patient’s risk for PIM, provide education about possible adverse outcomes of a PIM and then determine next steps based on the clinical scenario, patient goals, etc.
Based on previous reflection, the intervention has the buy-in of the preceptor, but there is acknowledgement of the complexity of the typical patient visit. Brief targeted reminders are preferable to repeated lengthy educational sessions because they are more compatible with the time constraints of primary care.
Further, it will be important for both the preceptor and student to explore whether flagged discrepancies represent prescribing issues, reasonable clinical exceptions, or lack of clear documentation. Regardless, it will be important for the preceptor and student to maintain the same description of qualifying patient visits, approach to unclear scenarios, criteria for determining if a PIM has been appropriately documented, etc throughout the 8-week implementation process for these reasons:
so that apparent improvements in PIM prescribing are not the result of modified data collection/chart review,
The aim is to accurately determine clinician knowledge regarding PIM and adherence to recommendations for avoiding PIM.
Further, modifications to the proposed project cannot be implemented without discussion with the appropriate parties. Changes to the data collected, qualifying scenarios, description of intervention, etc should first be discussed with the appropriate individuals, and approved modifications can then be implemented.
Estimated Practicum Time
Estimated planning time for week four is approximately 12 hours at the site and 18 hours of practicum log time. Site hours (12) may include discussions with the preceptor, chart review activities, audit tracker quality checks, brief provider feedback, and implementation support. Log-Time (6 hours) may include scholarly readings, analysis of de-identified project documentation, completion of Weekly Report, eligible meetings/communications with DNP Mentor, preceptor, professor, or associate dean. The estimated times listed above are based on the Week 1 estimated plan, rather than confirmed hours worked. Only eligible time should be logged as practicum time in the official practicum log, and hours should not be counted twice.
The purpose of Week 4 is to extend the work done during Weeks 2 & 3 and prepare the project for the next phase. The value added to this week will be demonstrated through documenting the quality of the medication review process, clinical reasoning regarding potentially inappropriate medications, and consistent data collection. There will be no assumed reduction in inappropriate medications prior to the final evaluation.
References
American Geriatrics Society Beers Criteria® Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052–2081. https://doi.org/10.1111/jgs.18372
American Association of Colleges of Nursing. (2006). The essentials of doctoral education for advanced nursing practice. https://www.aacnnursing.org/Portals/42/Publications/DNPEssentials.pdf
Costanzo, S., Di Castelnuovo, A., Panzera, T., De Curtis, A., Falciglia, S., Persichillo, M., Cerletti, C., Donati, M., De Gaetano, G., & Iacoviello, L. (2024). Polypharmacy in older adults: The hazard of hospitalization and mortality is mediated by potentially inappropriate prescriptions: Findings from the Moli-sani Study. International Journal of Public Health, 69, 1607682. https://doi.org/10.3389/ijph.2024.1607682
8 days ago
10
- Allen
- plagiarism knowledge quizz
- MGT 350 Week 4 DQ 2
- ACC 220 Week 3 CheckPoint Classified Balance Sheets
- Management Information Systems
- Evaluating Measure of Central Tendency
- evaluate the economic cost to the U.S. due to investigating Mad Cow Disease, and determine whether or not diligent monitoring can safeguard against damaging the U.S. meat supplies. Provide at least two (2) examples to support your rationale.
- For Prof. Goodman Only
- One question
- "Quality at the Job"